Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
NEW YORK, April 11, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Central District of California on behalf of investors who purchased Cardiovascular Systems, Inc. (NASDAQ:CSII) securities between September 12, 2011 and January 21, 2016.
Click here to learn about the case: http://docs.wongesq.com/CSII-Info-Request-Form-1119. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period Defendants issued false and misleading statements to investors and/or failed to disclose that: (1) Cardiovascular Systems distributed illegal kickbacks to health care providers; (2) Cardiovascular Systems engaged in the off-label promotion of its medical devices; and (3) Cardiovascular Systems violated FDA laws and regulations in connection with its medical devices. As a result of the foregoing, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Cardiovascular Systems you have until April 12, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/CSII-Info-Request-Form-1119.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
